mutational clonality and intratumour heterogeneity as biomarkers for cancer immunotherapy
Published 8 years ago • 687 plays • Length 5:23Download video MP4
Download video MP3
Similar videos
-
32:54
role of genomics in identifying biomarkers for response and resistance to anti-cancer immunotherapy
-
8:52
multiplex ihc as biomarkers for cancer immunotherapy
-
24:18
immunotherapy biomarkers and patient selection
-
6:47
new biomarkers for response to immunotherapy
-
1:25
tumor mutational burden (tmb): a predictive biomarker for lung cancer immunotherapy response
-
5:16
predictive biomarkers for immunotherapy in upper gi cancers
-
49:06
"revisiting the neoantigen approach for cancer immunotherapy" by dr. yardena samuels
-
2:42
tumor mutation burden (tmb)- a biomarker for cancer immunotherapy!
-
1:14:51
the present and the future of cancer immunotherapy biomarkers
-
1:15
dr. hamid on tmb as a biomarker for immunotherapy response in melanoma
-
42:53
biomarkers in cancer immunotherapy: how much do they matter?
-
0:48
immune checkpoint inhibitors: recent progress and potential biomarkers - 4i neoantigens
-
0:46
immune checkpoint inhibitors: recent progress and potential biomarkers - 3iv pd-l1 overexpression
-
17:00
stat115 chapter 27.4 cancer immunotherapy response biomarkers
-
12:12
cancer immunotherapy workshop 2021 – multi-omic biomarker analysis for tumor and immune learnings
-
1:15
exploring biomarkers for immunotherapy treatment in lung cancer
-
16:35
heterogeneity of nsclc and precipitating oncogenic driver mutations
-
1:11:32
refining best practices in cancer immunotherapy biomarker testing and pathologic response assessment
-
0:36
immune checkpoint inhibitors: recent progress and potential biomarkers - 3ii pd-l1 overexpression